胰高血糖素:百年密集研究与争议的过去与现在
2022年是胰高血糖素发现100周年,本文回顾其发现、纯化、结构、α细胞来源、放射免疫测定、GCG基因及GLR受体的历史,并综述其作为抗胰岛素激素治疗1型糖尿病低血糖昏迷、在2型糖尿病病理生理中的作用及靶向策略的演进。
要点
- 胰高血糖素发现百年,早期基础研究涉及三位诺贝尔奖得主。
- 胰高血糖素曾用于治疗1型糖尿病胰岛素诱导的低血糖昏迷。
- 靶向胰高血糖素的策略包括GLP1R激动剂及GLP1R/GLR双激动剂。
核心结论
- 胰高血糖素百年故事很可能尚未结束。
研究设计与样本
- TimeCapsule综述,回顾胰高血糖素发现、表征及临床重要性的主要步骤。
主要发现
- 2022年为胰高血糖素发现100周年。
- 早期基础研究包括发现、纯化、结构、α细胞来源、放射免疫测定、GCG基因及GLR受体。
- 胰高血糖素被视为抗胰岛素激素,曾用于治疗1型糖尿病胰岛素诱导的低血糖昏迷。
- 胰高血糖素及α细胞在2型糖尿病生理和病理生理(旁分泌病变)中作用被发现。
- GLP1R激动剂是靶向胰高血糖素策略的重大突破,并出现抑制胰高血糖素分泌联合葡萄糖依赖性刺激胰岛素分泌的策略。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
2022 corresponds to the 100th anniversary of the discovery of glucagon. This TimeCapsule aims to recall the main steps leading to the discovery, characterisation, and clinical importance of the so-called second pancreatic hormone. We describe the early historical findings in basic research (ie, discovery, purification, structure, α-cell origin, radioimmunoassay, glucagon gene [GCG], and glucagon receptor [GLR]), in which three future Nobel Prize laureates were actively involved. Considered as an anti-insulin hormone, glucagon was rapidly used to treat insulin-induced hypoglycaemic coma episodes in people with type 1 diabetes. A key step in the story of glucagon was the discovery of its role and the role of α cells in the physiology and pathophysiology (ie, paracrinopathy) of type 2 diabetes. This concept led to the design of different strategies targeting glucagon, among which GLP-1 receptor (GLP1R) agonists were a major breakthrough, and combination of inhibition of glucagon secretion with stimulation of insulin secretion (both in a glucose-dependent manner). Taking advantage of the glucagon-induced increase in energy metabolism, biased coagonists were developed. Besides the GLP-1 receptor, these coagonists also target the glucagon receptor to further promote weight loss. Thus, the 100-year story of glucagon has most probably not come to an end.
引用
- Scheen AJ, Lefèbvre PJ. Glucagon, from past to present: a century of intensive research and controversies. Lancet Diabetes Endocrinol. 2022. PMID: 36566754. doi:10.1016/S2213-8587(22)00349-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。